James William Burns Sells 2,799 Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) Stock

Agios Pharmaceuticals, Inc. (NASDAQ:AGIO - Get Free Report) insider James William Burns sold 2,799 shares of the stock in a transaction dated Tuesday, June 24th. The shares were sold at an average price of $33.54, for a total transaction of $93,878.46. Following the completion of the transaction, the insider now directly owns 28,650 shares of the company's stock, valued at approximately $960,921. This trade represents a 8.90% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this link.

Agios Pharmaceuticals Stock Down 0.5%

Shares of AGIO traded down $0.18 during mid-day trading on Friday, reaching $33.47. 489,988 shares of the company's stock were exchanged, compared to its average volume of 651,989. The company has a 50-day simple moving average of $31.27 and a two-hundred day simple moving average of $32.11. Agios Pharmaceuticals, Inc. has a 52-week low of $23.42 and a 52-week high of $62.58. The company has a market cap of $1.94 billion, a price-to-earnings ratio of 2.98 and a beta of 0.73.

Agios Pharmaceuticals (NASDAQ:AGIO - Get Free Report) last issued its quarterly earnings data on Thursday, May 1st. The biopharmaceutical company reported ($1.55) earnings per share for the quarter, topping analysts' consensus estimates of ($1.80) by $0.25. Agios Pharmaceuticals had a net margin of 1,798.26% and a negative return on equity of 2.75%. The business had revenue of $8.73 million during the quarter, compared to analysts' expectations of $9.86 million. As a group, equities research analysts predict that Agios Pharmaceuticals, Inc. will post -6.85 EPS for the current fiscal year.

Wall Street Analyst Weigh In

A number of research analysts have issued reports on the stock. Wall Street Zen cut shares of Agios Pharmaceuticals from a "hold" rating to a "sell" rating in a report on Monday, May 19th. Scotiabank dropped their target price on shares of Agios Pharmaceuticals from $74.00 to $71.00 and set a "sector outperform" rating for the company in a report on Friday, May 2nd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and five have given a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of "Moderate Buy" and an average price target of $58.60.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of AGIO. Jefferies Financial Group Inc. purchased a new position in shares of Agios Pharmaceuticals during the 4th quarter worth approximately $49,290,000. SCS Capital Management LLC purchased a new stake in Agios Pharmaceuticals in the 1st quarter worth approximately $17,905,000. Adage Capital Partners GP L.L.C. grew its stake in Agios Pharmaceuticals by 145.2% in the 1st quarter. Adage Capital Partners GP L.L.C. now owns 743,000 shares of the biopharmaceutical company's stock worth $21,770,000 after acquiring an additional 440,000 shares during the period. Palo Alto Investors LP purchased a new stake in Agios Pharmaceuticals in the 1st quarter worth approximately $8,104,000. Finally, Paradigm Biocapital Advisors LP purchased a new stake in Agios Pharmaceuticals in the 4th quarter worth approximately $9,084,000.

About Agios Pharmaceuticals

Agios Pharmaceuticals, Inc, a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes for the treatment of hemolytic anemias.